PrepSolution

Nursing · Study journal

FNP Musculoskeletal Practice Questions: Gout, Osteoarthritis and NSAIDs

Thirteen original FNP musculoskeletal questions on ACR 2020 gout rules, ACR/AF osteoarthritis recommendations, NSAID and colchicine label warnings, and USPSTF falls prevention.

By Elena R.Published Reviewed by PrepSolution Editorial Team10 min read
Inside this articleNursing
Section preview 01

Gout: when to start urate-lowering therapy

A 54-year-old has had three gout flares in the past year. He has no tophi. What does the ACR 2020 guideline recommend?

Read this section
On this page

Musculoskeletal items on the FNP boards often hide a medication decision inside a joint complaint. Gout questions ask when to start urate-lowering therapy and which drug to use; osteoarthritis questions ask which treatments the guideline supports and which it rejects; NSAID questions test the boxed warning.

These 13 questions are written for candidates using FNP-C exam prep. Older adults carry 30% of scored items on the NPCB blueprint, the largest age group, and most of these items are set in that group. The AANP FNP exam blueprint guide covers the full weighting.

This set is exam practice written from the guidelines, USPSTF recommendations and FDA labels listed under References. The questions are original PrepSolution items, not NPCB or ANCC exam questions. It is not clinical guidance for any patient, and it has not been reviewed by a credentialed nurse practitioner.

Gout: when to start urate-lowering therapy

Question 1: Frequent flares

A 54-year-old has had three gout flares in the past year. He has no tophi. What does the ACR 2020 guideline recommend?

  • A. Treat each flare and do not start ULT
  • B. Strongly recommend starting ULT
  • C. Start ULT only if tophi develop
  • D. Start ULT only after imaging shows joint damage

Best answer: B. ACR strongly recommends starting ULT for patients with frequent gout flares, defined as 2 or more a year. Tophi and radiographic damage are separate strong indications, not requirements.

  • A is not the best answer. Two or more flares a year is itself a strong indication for ULT.
  • C is not the best answer. Tophi are an indication on their own; their absence does not rule out ULT.
  • D is not the best answer. Radiographic damage is a separate indication, not a prerequisite.

Question 2: A first flare

A 47-year-old has his first gout flare. His serum urate is 8.1 mg/dL, kidney function is normal and he has no kidney stones. What does ACR 2020 recommend about ULT?

  • A. Strongly recommend starting ULT now
  • B. Start ULT only if urate stays above 6 mg/dL after the flare
  • C. Conditionally recommend against starting ULT
  • D. Start ULT if he is over 45

Best answer: C. For a first flare, ACR conditionally recommends against starting ULT, with exceptions for CKD stage 3 or worse, serum urate above 9 mg/dL, or urolithiasis. He has none of these.

  • A is not the best answer. The strong recommendation applies to tophi, radiographic damage or 2 or more flares a year.
  • B is not the best answer. A urate above 6 mg/dL is not one of the first-flare exceptions; the urate exception is above 9 mg/dL.
  • D is not the best answer. Age is not part of the recommendation.

Question 3: High urate, no gout

Routine labs show a serum urate of 7.9 mg/dL in a 60-year-old who has never had a gout flare or tophi. What does ACR 2020 recommend?

  • A. Conditionally recommend against starting pharmacologic ULT
  • B. Start allopurinol to prevent a first flare
  • C. Start febuxostat
  • D. Start probenecid

Best answer: A. For asymptomatic hyperuricemia, defined as serum urate above 6.8 mg/dL with no prior flares or tophi, ACR conditionally recommends against starting any pharmacologic ULT, including allopurinol, febuxostat and probenecid.

  • B is not the best answer. Allopurinol is one of the drugs ACR recommends against starting here.
  • C is not the best answer. Febuxostat is also named in the recommendation against.
  • D is not the best answer. Probenecid is also named in the recommendation against.

Gout: choosing and running therapy

Question 4: First-line ULT with CKD

A 72-year-old with tophaceous gout has CKD stage 3. Which drug does ACR 2020 recommend as first-line ULT?

  • A. Probenecid
  • B. Febuxostat, because of the CKD
  • C. Pegloticase
  • D. Allopurinol, including in CKD stage 3 or worse

Best answer: D. ACR strongly recommends allopurinol as the preferred first-line ULT, including for people with moderate to severe CKD (stage 3 or worse), started at a low dose and titrated.

  • A is not the best answer. Probenecid is not the preferred first-line agent.
  • B is not the best answer. CKD does not make febuxostat first-line; ACR names allopurinol for CKD stage 3 or worse.
  • C is not the best answer. Pegloticase is not first-line ULT.

Question 5: The urate target

A patient on allopurinol has a serum urate of 7.2 mg/dL after 2 months. What target does ACR 2020 use for dose titration?

  • A. Serum urate under 6 mg/dL
  • B. Serum urate under 8 mg/dL
  • C. No target; adjust by symptoms only
  • D. Serum urate under 4 mg/dL for everyone

Best answer: A. ACR strongly recommends a treat-to-target strategy, titrating ULT by serial serum urate measurements to a target under 6 mg/dL. At 7.2 mg/dL, the dose should be titrated up.

  • B is not the best answer. Under 8 mg/dL is above the ACR target.
  • C is not the best answer. ACR recommends titrating to a measured urate target, not by symptoms alone.
  • D is not the best answer. The guideline target is under 6 mg/dL.

Question 6: Flare prophylaxis when starting ULT

A 58-year-old is starting allopurinol. What does ACR 2020 strongly recommend alongside it?

  • A. No additional therapy
  • B. A loading dose of allopurinol
  • C. Anti-inflammatory prophylaxis for at least 3 to 6 months
  • D. Daily prednisone for 2 years

Best answer: C. When starting ULT, ACR strongly recommends concomitant anti-inflammatory prophylaxis for at least 3 to 6 months, because flares are common early in urate lowering.

  • A is not the best answer. ACR strongly recommends prophylaxis with ULT initiation.
  • B is not the best answer. ACR recommends a low starting dose of allopurinol, not a loading dose.
  • D is not the best answer. The recommended prophylaxis duration is at least 3 to 6 months, not 2 years.

Question 7: HLA-B*5801 testing

Before starting allopurinol, for which patient does ACR 2020 conditionally recommend HLA-B*5801 testing?

  • A. Every patient regardless of ancestry
  • B. A patient of Korean descent
  • C. Only patients with CKD stage 4
  • D. Only patients over 75

Best answer: B. ACR conditionally recommends HLA-B*5801 testing before allopurinol for patients of Southeast Asian descent (for example Han Chinese, Korean or Thai) and for African American patients. It conditionally recommends against universal testing in other groups.

  • A is not the best answer. ACR conditionally recommends against universal testing.
  • C is not the best answer. The recommendation is based on ancestry, not CKD stage.
  • D is not the best answer. Age is not part of the recommendation.

Question 8: Colchicine with an interacting drug

A 77-year-old with CKD and a gout flare takes clarithromycin, a strong CYP3A4 inhibitor. What does the colchicine label say?

  • A. Colchicine is safe at standard doses
  • B. Colchicine is preferred because NSAIDs are risky in CKD
  • C. Colchicine should be doubled to overcome the interaction
  • D. Patients with renal or hepatic impairment should not be given colchicine with P-gp or strong CYP3A4 inhibitors

Best answer: D. The Colcrys label contraindicates colchicine with P-gp or strong CYP3A4 inhibitors in patients with renal or hepatic impairment, because life-threatening and fatal toxicity has been reported at therapeutic doses.

  • A is not the best answer. The label reports fatal toxicity at therapeutic doses in this situation.
  • B is not the best answer. Concerns about NSAIDs do not override the colchicine contraindication.
  • C is not the best answer. Raising the dose increases the risk of toxicity.

Question 9: Febuxostat and heart disease

A 69-year-old with gout and prior myocardial infarction tolerates allopurinol well but his urate is not yet at target. What does the febuxostat label support?

  • A. Titrate allopurinol further; febuxostat is reserved for an inadequate response to maximally titrated allopurinol or intolerance
  • B. Switch to febuxostat now, since it is safer in heart disease
  • C. Add febuxostat to allopurinol
  • D. Start febuxostat because he had a heart attack

Best answer: A. The Uloric boxed warning reports a higher rate of cardiovascular death with febuxostat than with allopurinol in gout patients with established cardiovascular disease. The label limits febuxostat to patients with an inadequate response to a maximally titrated dose of allopurinol, intolerance to allopurinol, or for whom allopurinol is not advisable.

  • B is not the best answer. The boxed warning reports more cardiovascular deaths with febuxostat in established CV disease.
  • C is not the best answer. Combining two xanthine oxidase inhibitors is not supported by the label.
  • D is not the best answer. Heart disease is a reason for caution with febuxostat, not a reason to choose it.

Osteoarthritis, NSAIDs and falls

Question 10: First drug for knee osteoarthritis

A 68-year-old with knee osteoarthritis wants a medication for pain. Which choice does the ACR/AF 2019 guideline strongly recommend and suggest before oral NSAIDs?

  • A. Oral opioid
  • B. Glucosamine
  • C. Topical NSAID
  • D. Oral hydroxychloroquine

Best answer: C. ACR/AF strongly recommends topical NSAIDs for knee OA and says that, because local therapy has the least systemic exposure, topical NSAIDs should be considered before oral NSAIDs.

  • A is not the best answer. Opioids are not the preferred first medication in the guideline.
  • B is not the best answer. Glucosamine is strongly recommended against.
  • D is not the best answer. Hydroxychloroquine is not recommended for OA.

Question 11: Supplements for osteoarthritis

A 71-year-old with hip osteoarthritis asks whether to take glucosamine. What does the ACR/AF 2019 guideline say?

  • A. It is strongly recommended
  • B. It is conditionally recommended
  • C. It is recommended only with chondroitin
  • D. It is strongly recommended against

Best answer: D. ACR/AF strongly recommends against glucosamine in patients with knee, hip or hand OA.

  • A is not the best answer. The guideline recommends against glucosamine, not for it.
  • B is not the best answer. There is no conditional recommendation for glucosamine.
  • C is not the best answer. Combining it with chondroitin does not change the recommendation against glucosamine.

Question 12: NSAIDs and bypass surgery

Which situation is a contraindication to celecoxib on its label?

  • A. Mild seasonal allergies
  • B. The setting of coronary artery bypass graft (CABG) surgery
  • C. Age over 60
  • D. Osteoarthritis of the hand

Best answer: B. The Celebrex label carries a boxed warning for serious cardiovascular thrombotic events and serious GI bleeding, ulceration and perforation, and states celecoxib is contraindicated in the setting of CABG surgery.

  • A is not the best answer. Seasonal allergies are not a labeled contraindication.
  • C is not the best answer. Age alone is not a contraindication, though older adults carry higher GI risk.
  • D is not the best answer. Osteoarthritis is an indication, not a contraindication.

Question 13: Preventing falls

A 78-year-old living at home has fallen twice this year and is at increased risk for falls. Which intervention does USPSTF recommend with a B grade?

  • A. Exercise interventions
  • B. Vitamin D supplementation for all older adults
  • C. Routine multifactorial intervention for everyone
  • D. Hip protectors

Best answer: A. USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 and older at increased risk (Grade B). For multifactorial interventions, it recommends individualizing the decision (Grade C).

  • B is not the best answer. Vitamin D is not the recommended B-grade intervention in this statement.
  • C is not the best answer. USPSTF says to individualize multifactorial interventions, not offer them routinely.
  • D is not the best answer. Hip protectors are not part of the recommendation.

Gout decisions in one table

SituationACR 2020 recommendationStrength
Tophi, radiographic damage, or 2 or more flares a yearStart ULTStrong
First flare, no exceptionsDo not start ULTConditional
First flare with CKD stage 3 or worse, urate above 9, or stonesStart ULTConditional
Asymptomatic hyperuricemiaDo not start ULTConditional
Choice of first-line ULTAllopurinol, including CKD stage 3 or worseStrong
TargetSerum urate under 6 mg/dLStrong
Starting ULTProphylaxis for at least 3 to 6 monthsStrong
Flare treatmentColchicine, NSAIDs or glucocorticoidsStrong
ACR 2020 gout recommendations used in this set.

How should you use this set?

For gout items, first decide whether the stem describes an indication for ULT; most wrong answers start a drug too early or skip prophylaxis. For OA items, remember that the guideline also lists treatments it recommends against, and those make good distractors. Exercise and, for overweight patients with knee or hip OA, weight loss are both strongly recommended.

Boxed warnings for other drug classes are in our FNP pharmacology practice set, and pediatric musculoskeletal topics are left to the pediatrics set. For timed questions across every blueprint domain, see FNP-C exam prep.

Elena R.

PrepSolution Content Editor, Nurse Practitioner Certification

About PrepSolution

References

  1. [1] ACR (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. ACR. ACR
  2. [2] ACR/AF (2020). 2019 Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. ACR/AF. ACR/AF
  3. [3] USPSTF (2024). Falls Prevention in Community-Dwelling Older Adults: Interventions. USPSTF. USPSTF
  4. [4] FDA label (2026). Colcrys (colchicine). FDA label. FDA label
  5. [5] FDA label (2026). Uloric (febuxostat). FDA label. FDA label
  6. [6] FDA label (2026). Celebrex (celecoxib). FDA label. FDA label
  7. [7] NPCB (2026). FNP Candidate Handbook (June 2026). NPCB. NPCB

Help us improve this guide

How helpful was this article?

One tap helps us understand what’s useful.

Not helpful → Very helpful

Frequently asked questions

ACR 2020 strongly recommends it for tophi, radiographic damage from gout, or 2 or more flares a year.

Allopurinol, including for people with CKD stage 3 or worse, started at a low dose and titrated to a serum urate under 6 mg/dL.

Its label carries a boxed warning for a higher rate of cardiovascular death than allopurinol in patients with established cardiovascular disease, and limits it to people who cannot use or do not respond to allopurinol.

No. The 2019 ACR/AF guideline strongly recommends against glucosamine for knee, hip and hand OA.

USPSTF recommends exercise interventions for community-dwelling adults 65 and older at increased risk (Grade B).

No. They are original PrepSolution items written from the sources listed under References. They are not clinical guidance and have not been reviewed by a credentialed nurse practitioner.

Keep practicing for the FNP-C.

Review the study tools, access options and price, or start with free practice.

Related Articles